Biomerica, Inc. is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing.
Company profile
Ticker
BMRA
Exchange
Website
CEO
Zackary S. Irani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NMS PHARMACEUTICALS INC, NUCLEAR MEDICAL SYSTEMS INC, NUCLEAR INSTRUMENTS INC
SEC CIK
Corporate docs
Subsidiaries
BioEurope GmbH • Biomerica de Mexico ...
IRS number
952645573
BMRA stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
25 Apr 23
10-Q
2023 Q3
Quarterly report
14 Apr 23
8-K
Biomerica Announces Proposed Underwritten
7 Mar 23
424B5
Prospectus supplement for primary offering
6 Mar 23
424B5
Prospectus supplement for primary offering
2 Mar 23
424B5
Prospectus supplement for primary offering
2 Mar 23
8-K
Departure of Directors or Certain Officers
2 Mar 23
8-K
Regulation FD Disclosure
7 Feb 23
10-Q
2023 Q2
Quarterly report
13 Jan 23
8-K/A
Submission of Matters to a Vote of Security Holders
29 Dec 22
Latest ownership filings
Financial summary
| Quarter (USD) | Feb 23 | Nov 22 | Aug 22 | May 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | May 22 | May 21 | May 20 | May 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 3.35 mm | 3.35 mm | 3.35 mm | 3.35 mm | 3.35 mm | 3.35 mm |
| Cash burn (monthly) | 573.77 k | 569.05 k | 550.39 k | 595.30 k | 574.93 k | 730.74 k |
| Cash used (since last report) | 1.91 mm | 1.89 mm | 1.83 mm | 1.98 mm | 1.91 mm | 2.43 mm |
| Cash remaining | 1.44 mm | 1.45 mm | 1.51 mm | 1.37 mm | 1.43 mm | 914.73 k |
| Runway (months of cash) | 2.5 | 2.6 | 2.8 | 2.3 | 2.5 | 1.3 |
Institutional ownership, Q4 2022
24.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 32 |
| Opened positions | 6 |
| Closed positions | 3 |
| Increased positions | 11 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 10.93 bn |
| Total shares | 4.06 mm |
| Total puts | 3.60 k |
| Total calls | 42.80 k |
| Total put/call ratio | 0.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Granahan Investment Management | 1.12 mm | $3.76 bn |
| Wasatch Advisors | 574.97 k | $1.93 bn |
| Palm Management | 571.43 k | $1.56 mm |
| Vanguard | 546.16 k | $1.83 bn |
| Point72 Asset Management | 420.00 k | $1.41 bn |
| BLK Blackrock | 181.93 k | $609.46 mm |
| Geode Capital Management | 90.82 k | $304.00 k |
| Heritage Investors Management | 70.35 k | $236.00 k |
| Russell Investments | 63.77 k | $213.62 mm |
| Ridgewood Investments | 60.00 k | $201.00 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 May 23 | Zackary S. Irani | Common Stock | Buy | Acquire P | No | No | 1.55 | 200 | 310.00 | 1,020,560 |
| 24 May 23 | Zackary S. Irani | Common Stock | Buy | Acquire P | No | No | 1.61 | 500 | 805.00 | 1,020,360 |
| 12 May 23 | Zackary S. Irani | Common Stock | Buy | Acquire P | No | No | 1.17 | 1,700 | 1.99 k | 1,019,860 |
| 10 May 23 | Zackary S. Irani | Common Stock | Buy | Acquire P | No | No | 1.27 | 500 | 635.00 | 1,018,160 |
| 9 May 23 | Zackary S. Irani | Common Stock | Buy | Acquire P | No | No | 1.39 | 300 | 417.00 | 1,017,660 |
| 4 May 23 | Zackary S. Irani | Common Stock | Buy | Acquire P | No | No | 1.36 | 1,000 | 1.36 k | 1,017,360 |
News
12 Health Care Stocks Moving In Friday's Intraday Session
19 May 23
Biomerica Inc. Announces Advances In inFoods IBS Test Now Validated For Use With Simple Finger Stick Whole Blood Collection Technology
18 May 23
Stocks That Hit 52-Week Lows On Monday
15 May 23
Stocks That Hit 52-Week Lows On Friday
12 May 23
Stocks That Hit 52-Week Lows On Monday
17 Apr 23
Press releases
inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology
18 May 23
Biomerica's inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).
17 Apr 23
Biomerica Reports Q3 Fiscal 2023 Results
14 Apr 23